MedTrace Logo

Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection

NCT04447235 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2022-08-09

No results posted yet for this study

Summary

Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19

Conditions

Interventions

DRUG

Placebo

Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients

DRUG

Ivermectin

Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients

DRUG

Losartan

Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients

Sponsors & Collaborators

  • Instituto do Cancer do Estado de São Paulo

    lead OTHER

Principal Investigators

  • Pedro Exman, MD · Instituto do Cancer do Estado de São Paulo

  • Maria del Pilar Diz, MD, PhD · Instituto do Cancer do Estado de São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-23
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04447235 on ClinicalTrials.gov